Cargando…

Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation

Pirfenidone is a pleiotropic molecule approved to treat idiopathic pulmonary fibrosis (IPF). Pirfenidone has demonstrated to downregulate transforming growth factor-β1 (TGF-β1) cellular effects. However, its anti-fibrotic mechanism remains unclear. Here, we aim to analyze the effects of pirfenidone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ballester, Beatriz, Milara, Javier, Cortijo, Julio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170494/ https://www.ncbi.nlm.nih.gov/pubmed/32341751 http://dx.doi.org/10.18632/oncotarget.27526

Ejemplares similares

MUC16 Is Overexpressed in Idiopathic Pulmonary Fibrosis and Induces Fibrotic Responses Mediated by Transforming Growth Factor-β1 Canonical Pathway
por: Ballester, Beatriz, et al.
Publicado: (2021)

MUC1 deficiency mediates corticosteroid resistance in chronic obstructive pulmonary disease
por: Milara, Javier, et al.
Publicado: (2018)

The role of mucin 1 in respiratory diseases
por: Ballester, Beatriz, et al.
Publicado: (2021)

Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets
por: Ballester, Beatriz, et al.
Publicado: (2019)

Mucins as a New Frontier in Pulmonary Fibrosis
por: Ballester, Beatriz, et al.
Publicado: (2019)

Anti-Inflammatory and Anti-Fibrotic Profile of Fish Oil Emulsions Used in Parenteral Nutrition-Associated Liver Disease
por: Pastor-Clerigues, Alfonso, et al.
Publicado: (2014)

Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone
por: Ma, Hsiao-Yen, et al.
Publicado: (2023)

The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1
por: Xi, Yue, et al.
Publicado: (2021)

Anti-fibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts
por: Zhou, Chaoming, et al.
Publicado: (2016)

The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC
por: Marwitz, Sebastian, et al.
Publicado: (2020)

Role and New Insights of Pirfenidone in Fibrotic Diseases
por: Lopez-de la Mora, David Alejandro, et al.
Publicado: (2015)

The in vitro anti-fibrotic effect of Pirfenidone on human pterygium fibroblasts is associated with down-regulation of autocrine TGF-β and MMP-1
por: Tao, Yijin, et al.
Publicado: (2020)

Pressure overload induced right ventricular remodeling is not attenuated by the anti-fibrotic agent pirfenidone
por: Andersen, Stine, et al.
Publicado: (2019)

The pan-JAK inhibitor LAS194046 reduces neutrophil activation from severe asthma and COPD patients in vitro
por: Milara, Javier, et al.
Publicado: (2022)

The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts
por: Mediavilla-Varela, Melanie, et al.
Publicado: (2016)

Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
por: Molina-Molina, M., et al.
Publicado: (2018)

Pirfenidone Has Anti-fibrotic Effects in a Tissue-Engineered Model of Human Cardiac Fibrosis
por: Bracco Gartner, Thomas C. L., et al.
Publicado: (2022)

Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro
por: Wei, Qilu, et al.
Publicado: (2021)

A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases
por: Shah, Parth V, et al.
Publicado: (2021)

Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1
por: Jin, Jin, et al.
Publicado: (2019)

Correction to: Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro
por: Wei, Qilu, et al.
Publicado: (2021)

The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?
por: Ferrara, Francesco, et al.
Publicado: (2020)

Pirfenidone, an Anti-Fibrotic Drug, Suppresses the Growth of Human Prostate Cancer Cells by Inducing G(1) Cell Cycle Arrest
por: Ishii, Kenichiro, et al.
Publicado: (2019)

The Role of JAK/STAT Molecular Pathway in Vascular Remodeling Associated with Pulmonary Hypertension
por: Roger, Inés, et al.
Publicado: (2021)

Senescence Alterations in Pulmonary Hypertension
por: Roger, Inés, et al.
Publicado: (2021)

Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms
por: Montero, Paula, et al.
Publicado: (2021)

Aclidinium inhibits human lung fibroblast to myofibroblast transition
por: Milara, Javier, et al.
Publicado: (2011)

Nitric Oxide System and Bronchial Epithelium: More Than a Barrier
por: Bayarri, María Amparo, et al.
Publicado: (2021)

Roflumilast Prevents the Metabolic Effects of Bleomycin-Induced Fibrosis in a Murine Model
por: Milara, Javier, et al.
Publicado: (2015)

Molecular and Clinical Predictors of Quality of Life in Chronic Rhinosinusitis with Nasal Polyps
por: Brunet, Aina, et al.
Publicado: (2023)

Influence of dose and exposition time in the effectiveness of N-Acetyl-l-cysteine treatment in A549 human epithelial cells
por: Montero, Paula, et al.
Publicado: (2023)

Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and/or anti-SARS-CoV-2
por: Antar, Samar A., et al.
Publicado: (2022)

Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist
por: Milara, Javier, et al.
Publicado: (2015)

The JAK2 pathway is activated in idiopathic pulmonary fibrosis
por: Milara, Javier, et al.
Publicado: (2018)

Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis
por: Estornut, Cristina, et al.
Publicado: (2022)

Evaluation of Delayed-Type Hypersensitivity to Antineoplastic Drugs—An Overview
por: Roger, Inés, et al.
Publicado: (2023)

IL-11 system participates in pulmonary artery remodeling and hypertension in pulmonary fibrosis
por: Milara, Javier, et al.
Publicado: (2022)

Design and rationale of a randomised, double-blind trial of the efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis
por: Fernández Pérez, Evans R., et al.
Publicado: (2021)

In vitro anti-inflammatory effects of AZD8999, a novel bifunctional muscarinic acetylcholine receptor antagonist /β2-adrenoceptor agonist (MABA) compound in neutrophils from COPD patients
por: Milara, Javier, et al.
Publicado: (2019)

Inhibition of Ureteral Stricture by Pirfenidone-Loaded Nanoparticle-Coated Ureteral Stents with Slow-Release Pirfenidone
por: Jiang, Zhaosheng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jkgb17nai16caqij3cu21soe5s